Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

News Article | May 8, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled "notch binding agents and antagonists and methods of use thereof." Allowed under the application are composition of matter and method of use claims related to the Company's humanized anti-Notch 3 antibodies, including AV-353. The U.S. patent scheduled to issue from this application will expire December 19, 2032, with the potential for extension to December 19, 2037. AV-353 is a potent inhibitory antibody specific to Notch 3, a pathway implicated in multiple diseases, including Pulmonary Arterial Hypertension (PAH). In preclinical studies, AV-353 has demonstrated the ability to potentially reverse the PAH disease phenotype, which would represent a potential disease-modifying approach to treatment. PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow. “AV-353’s disease modifying properties have the potential to transform the future treatment of PAH, a debilitating disorder for which current therapies target only symptoms,” said Michael Bailey, president and chief executive officer of AVEO. “AV-353’s selectivity and high affinity to Notch 3, which are unique from other approaches targeting the Notch pathway, have enabled us to build an increasingly broad patent estate around the program. Consistent with our strategic focus on oncology, we continue to engage with potential partners around the worldwide development of this important therapeutic candidate.” AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company’s website at www.aveooncology.com. This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “could,” “should,” “seek,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the qualities, uniqueness, expected benefits and potential of AV-353; the potential for AV-353 to be a disease-modifying treatment; the potential for AV-353 to transform treatment paradigms; AVEO’s plans to partner AV-353 and AVEO’s focus on developing oncology therapeutics. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEO’s ability to enter into new partnerships and maintain its licensing agreements, including for AV-353, and its ability, and the ability of its licensees, to achieve development and commercialization objectives under these arrangements; AVEO’s ability, and the ability of its licensees, to demonstrate to the satisfaction of applicable regulatory agencies the safety, efficacy and clinically meaningful benefit of AVEO’s product candidates; AVEO’s ability to successfully implement its strategic plans; AVEO’s ability to successfully enroll and complete clinical trials of its product candidates; AVEO’s ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO’s ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments, expenses and outcomes related to AVEO’s ongoing shareholder litigation; AVEO’s ability to raise the substantial additional funds required to achieve its goals; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.


News Article | May 4, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study of tivozanib in renal cell cancer (RCC), expected in the first quarter of 2018,” said Michael Bailey, president and chief executive officer of AVEO. “TIVO-3, which is designed to serve as the basis for a potential U.S. registration of tivozanib as a first- and third-line treatment for RCC, remains on track to complete enrollment and a pre-planned interim futility analysis in June of this year. We also look forward to several other potential key milestones this year, including completion of the Phase 1 portion of the Phase 1/2 TiNivo trial a tivozanib-nivolumab combination study in RCC, a regulatory decision in Europe for marketing approval of tivozanib as a first line treatment for RCC, and notable progress in our pipeline programs.” Mr. Bailey continued: “Among our pipeline programs, we look forward to two planned ficlatuzumab data presentations from investigator sponsored studies at ASCO, one in head and neck cancer and the other in acute myeloid leukemia. Ficlatuzumab, which targets Hepatocyte Growth Factor (HGF) with high affinity and specificity to inhibit HGF/c-Met biological activities, continues to attract investigator interest.” AVEO also announced today that Keith S. Ehrlich, the Company’s Chief Financial Officer, will be retiring from the Company, effective July 1, 2017. The Company has initiated a search for a new chief financial officer. Michael Bailey, the Company’s President and CEO, will assume certain of Mr. Ehrlich’s duties on an interim basis, to the extent a new chief financial officer has not been named by the time of Mr. Ehrlich’s retirement. Mr. Bailey added: “We greatly appreciate Keith’s contributions to AVEO and wish him well in his future endeavors. His leadership and guidance through a period of turnaround for the Company have been greatly valued. We look forward to a completing the search for a new chief financial officer as expeditiously as possible.” We believe that our $33.4 million in cash resources would allow us to fund our planned operations into the second quarter of 2018. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company’s website at www.aveooncology.com. This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “could,” “should,” “would,” “seek,” “look forward,” “advance,” “goal,” “strategy,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about AVEO’s and its collaborators’ future discovery, development and commercialization plans and efforts, including without limitation with respect to tivozanib, ficlatuzumab and AVEO’s other programs and platforms; and AVEO’s strategy, prospects, plans and objectives; the timing of the completion of enrollment and the data readout for the TIVO-3 trial; the timing of the completion of the Phase 1 portion of the TiNivo trial; and the Company’s cash runway. AVEO has based its expectations and estimates on assumptions that may prove to be incorrect. As a result, readers are cautioned not to place undue reliance on these expectations and estimates. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to AVEO’s ability to enter into and maintain its third party collaboration agreements, and its ability, and the ability of its licensees and other partners, to achieve development and commercialization objectives under these arrangements; AVEO’s ability, and the ability of its licensees, to demonstrate to the satisfaction of applicable regulatory agencies the safety, efficacy and clinically meaningful benefit of AVEO’s product candidates; AVEO’s ability to successfully enroll and complete clinical trials, including the TIVO-3 and TiNivo studies; AVEO’s ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO’s ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments, expenses and outcomes related to AVEO’s ongoing shareholder litigation; AVEO’s ability to successfully implement its strategic plans; AVEO’s ability to raise the substantial additional funds required to achieve its goals, including those goals pertaining to the development and commercialization of tivozanib; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s Annual Report on Form 10-K for the year ended December 31, 2016, its quarterly reports on Form 10-Q and in other filings that AVEO may make with the SEC in the future. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.


News Article | February 23, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the study’s Safety Monitoring Committee (SMC). The SMC concluded that no safety concern was observed for tivozanib and recommended that the study replace the small number of patients who dropped out prior to starting treatment. As recently announced, the TIVO-3 trial is enrolling substantially ahead of schedule, and with the SMC recommendation to replace early dropouts the Company still expects to complete enrollment in June 2017, ahead of its prior guidance of August 2017. A pre-planned futility analysis of the trial is expected around midyear 2017, with topline data expected in the first quarter of 2018. The TIVO-3 trial, together with the previously completed TIVO-1 trial of tivozanib in the first line treatment of RCC, is designed to support regulatory approval of tivozanib in the U.S. as first and third line treatment for RCC. “Tivozanib is a unique molecule in that its high selectivity for VEGF is designed to reduce off target toxicity, thereby increasing tolerability and its combinability with other agents, such as immunotherapies,” said Michael Needle, M.D., chief medical officer of AVEO. “We are very pleased to see the pace at which TIVO-3 is enrolling, and that it has completed its first safety review. We look forward to the futility analysis around midyear, and to other potential achievements in our tivozanib clinical program, including the expected first patient treated in the tivozanib and Opdivo® combination study, TiNivo, in early March.” Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been investigated in several tumors types, including renal cell, colorectal and breast cancers. The Phase 3 TIVO-3 trial is a pivotal, randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The trial is expected to enroll approximately 322 patients with recurrent RCC who have failed at least two prior regimens, including VEGFR-TKI therapy (other than sorafenib). Eligible patients may also have received checkpoint inhibitor therapy in earlier lines of treatment. Patients will be randomized 1:1 to receive either tivozanib or sorafenib, with no crossover between arms. The primary endpoint of the study is progression free survival. Secondary endpoints include overall survival, overall response rate, and safety and tolerability. The TIVO-3 trial, together with the previously completed TIVO-1 trial of tivozanib in the first line treatment of RCC, is designed to support regulatory approval of tivozanib in the U.S. as a first and third line treatment for RCC. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). For more information, please visit the company’s website at www.aveooncology.com. This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," "potential", "could," "should," “would,” "seek," “look forward,” “advance,” “goal,” “strategy,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others: the expected timelines for completing enrollment, undergoing a futility analysis and receiving top-line data readouts in TIVO-3; the potential for the design of the TIVO-3 and TIVO-1 trials to support regulatory approval for first and third line indications in RCC in the U.S.; AVEO’s plans to open clinical trial sites and begin dosing patients in the TiNIVO trial in March 2017, and the potential advancement of such trial; plans and strategies of AVEO and its partners and the potential achievement by AVEO and its partners of clinical, regulatory, commercial, manufacturing and other development goals and milestones; and the potential safety, efficacy, tolerability and other benefits of tivozanib in the treatment of renal cell carcinoma as a single agent or in combination with other therapies;. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to AVEO's ability to enter into and maintain its third party collaboration agreements, and its ability, and the ability of its licensees and other partners, to achieve development and commercialization objectives under these arrangements; AVEO's ability, and the ability of its licensees, to demonstrate to the satisfaction of applicable regulatory agencies the safety, efficacy and clinically meaningful benefit of AVEO's product candidates; AVEO's ability to successfully enroll and complete clinical trials, including the TIVO-3 and TiNivo studies; AVEO's ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO's ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments, expenses and outcomes related to AVEO's ongoing shareholder litigation; AVEO's ability to successfully implement its strategic plans; AVEO's ability to raise the substantial additional funds required to achieve its goals, including those goals pertaining to the development and commercialization of tivozanib; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled "Risk Factors" in AVEO's most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO's views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.


Hollywood, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"),   an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is proud to announce that four new scientists and doctors have joined the company’s Advisory Board. ETST strategy of recruiting industry experts to help expand and increase the Development of Cannabinoids' Therapeutic Indications, R&D, Technology, IP and Treatments. These Four Distinguished Scientists and Doctors will serve on the board of advisory for Earth Science Tech and or its two (2) wholly owned subsidiaries, Cannabis Therapeutics Inc., and Earth Science Pharmaceutical Inc. Dr. Laurent Azoulay, PhD. Laurent Azoulay, Ph.D., has joined both the Cannabis Therapeutics Inc. and Earth Science Pharmaceutical Inc. Advisory Boards. He is an Associate Professor of Oncology at McGill University, where he actively researches cancer pharmacoepidemiology, which includes evaluating the safety of cancer drugs at a societal level. After receiving his PhD in 2007 from the Université de Montréal, he completed a postdoctoral fellowship in pharmacoepidemiology at the Department of Epidemiology, Biostatistics and Occupational Health, McGill University. He then joined the Gerald Department of Oncology as an Assistant Professor in 2009. In 2016, he was promoted to the rank of Associate Professor with a cross-appointment with the Department of Epidemiology, Biostatistics and Occupational Health. Dr. Chandra Panchal, PhD. Chandra Panchal, Ph.D., has joined the Cannabis Therapeutics Inc., Earth Science Pharmaceutical Inc., and Earth Science Tech Inc. Advisory Boards. He is a serial entrepreneur with a wealth of expertise acquired from 28 years of experience in the biotech/pharmaceutical sector. Dr. Panchal founded Axcelon in 2001 and was a co-founder of Procyon Biopharma Inc., a publicly traded biotechnology company involved in the development of wound healing, cancer therapeutic, and diagnostic products. Now known as Ambrilia BioPharma Inc., the company listed on the Alberta Stock Exchange in 1998 and the TSX in 2000. He served as Procyon Biopharma Inc.’s Chairman, President, and CEO; and Ambrilia Biopharma Inc.’s Senior Executive Vice-President, Business Development, Licensing, and Intellectual Property in charge of both out-licensing, in-licensing and M&A activities. He retired from Ambrilia Biopharma Inc. in February 2008. Since then, Dr. Panchal has been actively involved in Axcelon.  Prior to founding Procyon Biopharma Inc., Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentations, and product development at John Labatt Ltd., a multinational food and beverage company. Dr. Panchal sits on the board of directors of several public and private companies.  He has authored/co-authored over 60 scientific papers and has edited a book entitled Yeast Strain Selection. Dr. Panchal has been an Adjunct Professor at the University of Western Ontario where he obtained his Ph.D. in biochemical engineering. Dr. Domenico Fuoco, PhD. Domenico Fuoco, Ph.D., has joined the Cannabis Therapeutics Inc. Advisory Board. Dr. Fuoco has over 16 years’ experience in the research and development of innovative solutions for the pharmaceutical industry. Dr. Fuoco trained at the prestigious Department of Oncology of McGill University Health Centre (MUHC) in Montreal, from 2012 to 2015. During this time, Dr. Fuoco worked on the next generation of medications for AVEO Oncology and Helsinn Therapeutics.  Prior to this, Dr. Fuoco obtained his PhD and Post-Doc training in medicinal chemistry and drug discovery at the University of Perugia in Italy with further studies at the University of Salamanca School of Pharmacy in Spain. Dr. Fuoco is recognized for the transdisciplinary approach of his work. In 2010, Dr. Fuoco was Principal Scientist of the Italian Mission in Amazonia, Bogotà, Colombia.  Dr. Fuoco’s publications cover a wide-range of chemical fields, from functional foods to autoimmune diseases. In 2015, Dr. Fuoco was honored with the prestigious Dr. Henry Shibata Fellowship from the Cedar Cancer Foundation for his work in the field of palliative care. Dr. Fuoco is an active member of the Italian Canadian Community Foundation and is very active within his community.  He is also the chairman from Smart Medicines Consortium for the advancement of health care. Dr. Fuoco’s expertise in human health and functional foods are highly valued as strategic assets by ETST. Calvin Higgins, M.D. Calvin Higgins, M.D., has joined the Earth Science Tech Inc. Advisory Board. Dr. Calvin Higgins is board-certified in internal medicine. Diplomate of the American Board of Internal Medicine. He was born in Kingston, Jamaica. He came to the United States in 1979. He attended Cornell Medical School and graduated in 1985. In 1998, he completed his residency at Lenox Hill Medical Center in Manhattan, New York in Internal Medicine. In 1998 he moved to Florida and completed 3 years in office-based medicine. He then moved onto hospital-based medicine in 2001 to present. Dr. Higgins is affiliated with Memorial Hospital Miramar, Memorial Hospital Pembroke, Memorial Hospital West and Memorial Regional Hospital. Dr. Higgins has a great core for alternative medicine. He always encourages his patients to seek lifestyle changes in diet, exercise, meditation and mental wellness, just to name a few. “We are very excited to have so much new talent joining our Advisory Boards,” said President, Director, and COO Nickolas Tabraue, “We are well on our way to developing top-notch treatments to some of the most common health problems people face, and bringing on such esteemed talent to advise us will only get us there quicker.” About Earth Science Tech: (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Mayer E.L.,Dana-Farber Cancer Institute | Scheulen M.E.,University of Duisburg - Essen | Beckman J.,Brigham and Women's Hospital | Richly H.,University of Duisburg - Essen | And 7 more authors.
Breast Cancer Research and Treatment | Year: 2013

Tivozanib is a potent selective tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. This Phase Ib study investigated the safety/tolerability, pharmacokinetics (PK), and activity of tivozanib with weekly paclitaxel in metastatic breast cancer (MBC). MBC patients with no prior VEGFR TKI treatment received daily oral tivozanib (3 weeks on, 1 week off) with weekly paclitaxel 90 mg/m2. Standard 3 + 3 dose escalation was used; tivozanib cohorts (C) included C1 0.5 mg, C2 1.0 mg, and C3 1.5 mg. Assessments included Response Evaluation Criteria in Solid Tumors response, PK, and vascular function. Eighteen patients enrolled. Toxicities in >20 % of patients included fatigue, alopecia, nausea, diarrhea, peripheral sensory neuropathy, and hypertension. Grade 3/4 toxicities in >15 % of patients included fatigue and neutropenia. Maximum tolerated dose was tivozanib 1.5 mg with paclitaxel 90 mg/m2. Four patients withdrew because of toxicity and one due to progressive disease. Thirteen patients were evaluable for response: four (30.8 %) had confirmed partial response; four had stable disease ≥6 months (30.8 %). PK data suggest no influence of paclitaxel on tivozanib concentrations. Tivozanib plus weekly paclitaxel was tolerable at all dose levels, supporting their combination at full dose. Activity in this small population was encouraging. © 2013 Springer Science+Business Media New York.


Hollywood, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and development, through its wholly owned subsidiary, Cannabis Therapeutics, Inc., recently signed a joint venture with Smart Medicines GMP, which will allow the companies to explore synergies in researching and developing new CBD-based nutraceuticals and pharmaceutical compounds based on Earth Science Tech’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” which was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. Smart Medicines is equipped with a state-of-the-art laboratory and research facilities with high tech equipment and botanical extraction units. Smart Medicines will focus heavily on the research and development tasks associated with new product development. This partnership will help position Cannabis Therapeutics to be a global leader in the cannabis industry and in cannabinoid research and development. Cannabis Therapeutics’ imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). Smart Medicines is run by Dr. Domenico Fuoco, who recently joined the Advisory Board of Cannabis Therapeutics, Inc. (an Earth Science Tech subsidiary). Dr. Fuoco has over 16 years of extensive experience in developing innovative solutions for the pharmaceutical and nutraceutical industries in addition to his current status as a professional formulator. Dr. Fuoco and company’s expertise are expected to be of great benefit to Earth Science tech in its new product creation. View Dr. Fuoco’s full biography below. Smart Medicines and Earth Science Tech have close ties with CQIB (http://www.cqib.org/home.html), a biotech and life sciences incubator. They will work closely with CQIB to improve upon and further develop their patents while developing a stronger product portfolio. This relationship will further provide both companies access to top-of-the-line research and development equipment and laboratories to provide the most accurate of results. “We are excited to be getting so heavily involved with Dr. Domenico Fuoco and his company, Smart Medicines GMP,” said CEO Michael Aube, “We are working hard to establish a new line of strong nutraceutical and other CBD-based products, and we think this joint venture will be very lucrative for all parties.” Cannabis Therapeutics will work with Smart Medicines to invent and launch two new cannabinoid-based pharmaceutical drugs and three new advanced cannabinoid-based nutraceutical products using Earth Science Tech’s existing Cannabis CBD patent, IP, inventions, technology, and future technology. Cannabis Therapeutics’ primary goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases, Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer, immune cell function, and human brain cells by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. Dr. Domenico Fuoco, PhD.Domenico Fuoco, Ph.D., has joined the Cannabis Therapeutics Inc. Advisory Board. Dr. Fuoco has over 16 years’ experience in the research and development of innovative solutions for the pharmaceutical industry. Dr. Fuoco trained at the prestigious Department of Oncology of McGill University Health Centre (MUHC) in Montreal, from 2012 to 2015. During this time, Dr. Fuoco worked on the next generation of medications for AVEO Oncology and Helsinn Therapeutics. Prior to this, Dr. Fuoco obtained his PhD and Post-Doc training in medicinal chemistry and drug discovery at the University of Perugia in Italy with further studies at the University of Salamanca School of Pharmacy in Spain. Dr. Fuoco is recognized for the transdisciplinary approach of his work. In 2010, Dr. Fuoco was Principal Scientist of the Italian Mission in Amazonia, Bogotà, Colombia.  Dr. Fuoco’s publications cover a wide-range of chemical fields, from functional foods to autoimmune diseases. In 2015, Dr. Fuoco was honored with the prestigious Dr. Henry Shibata Fellowship from the Cedar Cancer Foundation for his work in the field of palliative care. Dr. Fuoco is an active member of the Italian Canadian Community Foundation and is very active within his community.  He is also the chairman from Smart Medicines Consortium for the advancement of health care. Dr. Fuoco’s expertise in human health and functional foods are highly valued as strategic assets by Cannabis Therapeutics Inc. and ETST. About Earth Science Tech: (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


PubMed | Nn Blokhin Cancer Research Center, AVEO Oncology, Poznan University of Medical Sciences and Texas Oncology Baylor Charles mmons Cancer Center
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2017

364 Background: Tivozanib hydrochloride (tivozanib) is a potent, selective, tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors, with a long half-life and has shown superior efficacy, measured as progression-free survival (PFS), as first-line, targeted therapy vs. sorafenib in a phase III trial (TIVO-1) in patients with advanced renal cell carcinoma (J Clin Oncol2012;30[suppl]:Abstract 4501). Patients who progressed (PD) on sorafenib could receive tivozanib in an open-label, prospective multicenter extension study of TIVO-1. We report preliminary efficacy and safety data for patients who had PD on sorafenib and subsequently received tivozanib in this extension study.Patients with PD on sorafenib, per RECIST version 1.0, were eligible to receive tivozanib dosed at 1.5 mg/day PO for 3 weeks followed by a 1-week rest, in repeated 4-week cycles, until PD or unacceptable toxicity. Patients were to have been no more than 4 weeks from last dose of sorafenib until initiation of tivozanib, and have an ECOG performance status of 2. Dose adjustments were performed as previously reported. Objectives included assessing objective response rate (ORR), duration of response, PFS for tivozanib following PD on sorafenib, and overall survival.As of January 20, 2012, 127 patients (72.4% male) were evaluable for response. Median age was 59.0 years (range: 23-85 years). ORR was 7.9% (95% CI 3.8-14.0%; partial response [PR]=7.9%; stable disease [SD]=65.4%; PD=18.9%), and 71.3% of patients showed tumor shrinkage. Median duration of PR was 11.1 months (95% CI 7.5 months). Median duration of SD was 12.7 months (95% CI 7.4 months). Median PFS was 5.6 months (95% CI 5.4-9.1 months). Median OS was not yet reached. Most commonly reported treatment-emergent adverse events (all grades/Grade 3) were hypertension (22.4%/10.2%), asthenia (11.0%/3.1%), fatigue (11.0%/3.9%), palmar-plantar erythrodysesthesia (11.0%/1.6%), and diarrhea (10.2%/1.6%).Tivozanib has anti-tumor activity after PD on sorafenib. The adverse-event profile of tivozanib after sorafenib is similar to that observed in TIVO-1.NCT01076010.


CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day 120 List of Questions. The Day 120 List of Questions were issued by the Committee for Medicinal Products for Human Use (CHMP) as part of the centralized review process of the Marketing Authorization Application (MAA)


News Article | November 4, 2016
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016. “In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline, for which we have retained significant North American rights, and our non-oncology pipeline, which is being advanced through partnerships with disease-area experts,” said Michael Bailey, president and chief executive


News Article | November 22, 2016
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days followin

Loading AVEO Oncology collaborators
Loading AVEO Oncology collaborators